Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$276.39
-2.2%
$292.54
$253.30
$339.17
$148.80B0.491.85 million shs2.14 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$79.56
-1.9%
$75.95
$61.24
$82.41
$246.74B0.373.15 million shs4.49 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.98
-3.6%
$7.66
$5.01
$15.22
$1.30B2.686.75 million shs7.15 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%-2.56%-4.79%-6.38%-16.24%
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.00%-2.62%+1.39%+6.91%-1.20%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+1.01%-15.38%+14.99%-35.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$276.39
-2.2%
$292.54
$253.30
$339.17
$148.80B0.491.85 million shs2.14 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$79.56
-1.9%
$75.95
$61.24
$82.41
$246.74B0.373.15 million shs4.49 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.98
-3.6%
$7.66
$5.01
$15.22
$1.30B2.686.75 million shs7.15 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%-2.56%-4.79%-6.38%-16.24%
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.00%-2.62%+1.39%+6.91%-1.20%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+1.01%-15.38%+14.99%-35.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.32
Hold$304.4310.14% Upside
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.75
Moderate Buy$86.008.09% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.13
Hold$14.2979.02% Upside

Current Analyst Ratings Breakdown

Latest AMGN, NVAX, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Amgen Inc. stock logo
AMGN
Amgen
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform
8/28/2025
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$10.00
8/25/2025
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$328.00 ➝ $342.00
8/20/2025
Novavax, Inc. stock logo
NVAX
Novavax
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutralUnderperform$9.00 ➝ $7.00
8/6/2025
Amgen Inc. stock logo
AMGN
Amgen
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$305.00 ➝ $310.00
8/6/2025
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$330.00 ➝ $333.00
8/6/2025
Amgen Inc. stock logo
AMGN
Amgen
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$326.00 ➝ $317.00
7/23/2025
Amgen Inc. stock logo
AMGN
Amgen
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$252.00 ➝ $261.00
7/22/2025
Amgen Inc. stock logo
AMGN
Amgen
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$300.00 ➝ $305.00
7/22/2025
Novavax, Inc. stock logo
NVAX
Novavax
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$10.00 ➝ $9.00
7/21/2025
Amgen Inc. stock logo
AMGN
Amgen
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$315.00 ➝ $326.00
(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.45$30.37 per share9.10$10.93 per share25.29
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.56$6.29 per share12.64$13.18 per share6.04
Novavax, Inc. stock logo
NVAX
Novavax
$1.08B1.20N/AN/A($3.89) per share-2.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$12.2322.6012.922.4018.96%174.71%13.12%10/29/2025 (Estimated)
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.6629.9115.911.4614.68%32.84%12.87%11/11/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.283.5099.750.1139.20%-142.33%28.65%11/11/2025 (Estimated)

Latest AMGN, NVAX, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million
8/5/2025Q2 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.28$6.02+$0.74$2.65$8.86 billion$9.18 billion
7/29/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.09$1.09N/A$0.79$14.08 billion$14.46 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.44%N/A77.84%14 Years
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.011.27%N/A37.97%N/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest AMGN, NVAX, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/1/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.21%8/22/20258/22/20259/12/2025
7/29/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$0.50502%8/8/20258/8/20259/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
7.24
1.31
0.98
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.55
0.86
0.67
Novavax, Inc. stock logo
NVAX
Novavax
5.93
2.36
2.34

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.69%
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000538.36 million534.65 millionOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990162.42 million160.80 millionOptionable

Recent News About These Companies

Bayforest Capital Ltd Purchases New Stake in Novavax, Inc. $NVAX
Invesco Ltd. Boosts Stake in Novavax, Inc. $NVAX
Nuveen LLC Purchases New Position in Novavax, Inc. $NVAX
Novavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$276.39 -6.34 (-2.24%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$277.05 +0.66 (+0.24%)
As of 09/12/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$79.56 -1.54 (-1.90%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$79.68 +0.13 (+0.16%)
As of 09/12/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.98 -0.30 (-3.62%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$7.98 0.00 (-0.01%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.